Private and Self-Pay Arrangements Lead Treatment Access in South Korea In South Korea, the market is expected to remain dominated by private insurance and self-pay arrangements, which hold an 85% share in 2025
Phase 2 data suggest approximately a 24% weight reduction with Retatrutide versus approximately a 15% weight reduction with Semaglutide in STEP trials indirect cross-trial comparison only
This breaks down to $680 every month on the low end, or as high as $1,368 on the more expensive end of the spectrum
Delivered to your door, 100% online
Itou M, Kawaguchi T, Taniguchi E, Sata M
Association between different GLP-1 receptor agonists and acute pancreatitis: case series and real-world pharmacovigilance analysis